FTRE (Fortrea Holdings) Treasury Stock : $0 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Fortrea Holdings's treasury stock for the quarter that ended in Sep. 2024 was $0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Fortrea Holdings Treasury Stock Historical Data

The historical data trend for Fortrea Holdings's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Treasury Stock Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Fortrea Holdings Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Treasury Stock	Get a 7-Day Free Trial								-	-	-	-	-

Fortrea Holdings Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Fortrea Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (NAS:FTRE) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

K67:Germany

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Executives

James S. Hanson	officer: General Counsel	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Thomas Pike	officer: Chief Executive Officer	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Peter M Neupert	director	13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Betty D Larson	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE, CHICAGO IL 60661
R Andrew Eckert	director	THREE RAVINIA DRIVE, ATLANTA GA 30346
Edward A Pesicka	director	9120 LOCKWOOD BLVD, MECHANICSVILLE VA 23116
Amrit Ray	director	60 LEVERONI COURT, NOVATO CA 94949
Amanda M. Warren	officer: Chief Accounting Officer	8 MOORE DRIVE, DURHAM NC 27703
David Ross Smith	director	251 BALLARDVALE STREET, WILMINGTON MA 01887
Van Der Vaart Sandra D	director, officer: President and Secretary	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	director, officer: Executive Vice President	P O BOX 1017, CHARLOTTE NC 28201-1017
Laboratory Corp Of America Holdings	10 percent owner	358 S MAIN ST, BURLINGTON NC 27215
Jill G. Mcconnell	officer: Chief Financial Officer	8 MOORE DRIVE, DURHAM NC 27703
Mark A. Morais	officer: Chief Operating Officer	8 MOORE DRIVE, DURHAM NC 27703
Robert S. Pringle	officer: Treasurer	531 SOUTH SPRING STREET, BURLINGTON NC 27215